Wells Fargo Rates Viridian Therapeutics (VRDN) buy

Wells Fargo has upgraded VRDN's rating to 'Buy', setting a price target of $31, a 64.98% upside from the current price.

By EarningsIQ Research Desk · Published Jun 29, 2026, 1:00 PM EDT · Updated Jul 1, 2026, 2:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Wells Fargo rated Viridian Therapeutics, Inc. ($VRDN) "buy" with a $31 price target on June 29, 2026.

Since the rating, $VRDN is up 1.1% after 1 week, up 5.8% after 1 month and up 1.3% to date (from the $18.79 close on Jun 29, 2026).

VRDN Viridian Therapeutics, Inc.

$19.03 -37.97% year to date

Daily close · Oct 16, 2026

Key Points

Wells Fargo upgraded VRDN to 'Buy' with a new price target of $31, announced on June 29, 2026.
Wells Fargo's $31 price target implies 64.98% upside from Viridian Therapeutics, Inc.'s ($VRDN) current $18.79 share price.
VRDN shares traded near $17.90 on Monday, with notable institutional interest from funds like BlackRock and FMR LLC.
Insider transactions include buys by Fairmount Funds Management and sales by several top executives.

Get $VRDN trade alerts by text

We text you when insiders, Congress or big funds trade $VRDN. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Viridian Therapeutics, Inc. alert may contain errors. Disclosures

Wells Fargo analyst Derek Archila has raised the rating on VRDN to 'Buy' and set a price target of $31. This upgrade was announced on June 29, 2026, reflecting increased confidence in VRDN's potential.

Analyst rating track record

Wells Fargo vs. the S&P 500

YTD return -12.19% hypothetical

All-time return +10.56% S&P 500 +34.06%

vs. S&P 500 -23.50% behind the index

Hypothetical returns from Wells Fargo's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in VRDN

FMR LLC grew its holdings by 994,921 shares, ending with 15,379,377 shares worth about $300.8 million, a 6.9% increase. BlackRock, Inc. added 1,399,552 shares, bringing its total to 7,831,475 shares valued at approximately $153.2 million, marking a 21.8% increase. Bellevue Group AG also increased its stake by 2,367,617 shares, now holding 6,726,144 shares worth $131.6 million, a 54.3% boost. State Street Corp added 1,206,325 shares, reaching 4,672,885 shares valued at $91.4 million, a 34.8% increase. Vanguard Capital Management LLC opened a new position with 4,167,201 shares valued at $81.5 million.

Viridian Therapeutics, Inc. Stock Down 14.6%

Shares of VRDN traded near $17.90 on Monday. The stock has attracted considerable interest from institutional investors, as seen in the recent activity by major funds.

12-month forecast

$VRDN price target

Viridian Therapeutics, Inc. daily closes and this analyst's $31 target. Not advice.

Insider Buying and Selling at Viridian Therapeutics, Inc.

Fairmount Funds Management LLC purchased 1,176,470 shares on May 11, 2026, at an average price of $17.00. Meanwhile, several top executives, including Chief Legal Officer Jennifer Tousignant and CEO Stephen Mahoney, sold shares on March 3, 2026, at an average price of $30.19. Tousignant also bought 5,169 shares on the same day.

Analysts Set New Price Targets

On June 29, 2026, Wells Fargo upgraded VRDN to 'Buy' with a $31 price target. Evercore ISI Group maintained its 'Buy' rating with a $26 target on May 15, 2026. RBC Capital reiterated its 'Buy' stance with a $34 target on May 6, 2026. Truist Securities also maintained a 'Buy' rating, setting a $33 target on April 21, 2026.

Bottom Line

Wells Fargo's upgrade to 'Buy' and the new $31 price target highlights growing optimism about VRDN. Institutional activity and insider trades show active interest in the stock. Remember, analyst ratings are forward-looking opinions and may influence investor sentiment, but they are not guarantees of future performance.